Feasibility of Photofrin II as a radiosensitizing agent in solid tumors - Preliminary results

Moshe Schaffer, Birgit Ertl-Wagner, Pamela Manuela Schaffer, Ulrike Kulka, Giulio Jori, Ralf Wilkowski, Anton Hofstetter, Eckhart Dühmke

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Background: Photofrin II has been demonstrated to serve as a specific and selective radiosensitizing agent in in vitro and in vivo tumor models. We aimed to investigate the feasibility of a clinical application of Photofrin II. Material and Methods: 12 patients were included in the study (7 unresectable solid tumors of the pelvic region, 3 malignant gliomas, 1 recurrent oropharyngeal cancer, 1 recurrent adenocarcinoma of the sphenoid sinus). The dose of ionizing irradiation was 30-50.4 Gy; a boost irradiation of 14 Gy was added for the pelvic region. All patients were intravenously injected with 1 mg/kg Photofrin II 24 h prior to the commencement of radiotherapy. Magnetic resonance imaging (MRI) controls and in some cases positron emission tomography (PET) were performed in short intervals. The mean follow-up was 12.9 months. Results: No major adverse events were noted. Minor adverse events consisted of mild diarrhea, nausea and skin reactions. A complete remission was observed in 4/12 patients. A reduction in local tumor volume of >45% was achieved in 4/12 patients. Stable disease was observed in 4/12 patients. 1 patient showed local disease progression after 5 months. Conclusion: The early follow-up results are encouraging regarding the feasibility of the application of Photofrin II as a radiosensitizing agent.

Original languageEnglish
Pages (from-to)514-519
Number of pages6
Issue number11
StatePublished - 31 Oct 2006
Externally publishedYes


  • Ionizing irradiation
  • Photofrin II
  • Radiosensitizer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Feasibility of Photofrin II as a radiosensitizing agent in solid tumors - Preliminary results'. Together they form a unique fingerprint.

Cite this